• Merbromin and SARS-CoV-2 3CLpro: What Was Shown

  2026-10-12

  Chen and colleagues reported that merbromin inhibited the SARS-CoV-2 3CLpro protease in a biochemical screening study of approximately 6,000 compounds. The evidence supports enzyme-level inhibition and a mixed-type kinetic model, but it does not establish antiviral activity in cells, clinical benefit, or safety. The study also does not evaluate Thrombin or the supplied thrombin fragment.

• Bestatin’s Context-Dependent Angiogenic Signal

  2026-10-12

  A 2003 in vitro study found that bestatin enhanced microvascular endothelial tube formation in a fibrin matrix, despite its reported antiangiogenic activity in other models. The findings implicate aminopeptidases beyond CD13 but remain limited to a simplified cell-and-matrix system.

• Dabigatran Review: Evidence in Thromboembolic Disease

  2026-10-10

  The 2015 review by Enriquez and colleagues synthesizes clinical and pharmacological evidence for dabigatran, the first widely introduced oral direct thrombin inhibitor. Its central contribution is a comparative interpretation of predictable pharmacokinetics, reduced monitoring requirements, efficacy across thromboembolic indications, and safety considerations that distinguish dabigatran from vitamin K antagonists.

• Alternariol in Mycotoxin and Liver Fibrosis Research

  2026-10-09

  Alternariol (AOH) is an emerging Alternaria-associated mycotoxin studied across food safety, cellular toxicology, and liver disease research. Recent in vitro findings connect AOH and alternariol monomethyl ether with hepatic stellate-cell activation, while uncertainties remain regarding exposure, metabolism, mixture effects, and clinical relevance.

• Berberrubine and the Vitamin K Cycle in Thrombosis

  2026-10-09

  Wang et al. integrate a mouse thrombosis model, non-targeted metabolomics, coagulation measurements, and molecular docking to investigate how berberrubine may suppress thrombus formation. The study links the observed antithrombotic phenotype to metabolic pathways associated with the vitamin K catalytic cycle, while also showing why the proposed mechanism requires further biochemical and translational validation.

• AEBSF.HCl: Reading Protease Signals in Cell Death

  2026-10-08

  AEBSF.HCl is a broad-spectrum serine protease inhibitor whose value depends on careful separation of serine-protease effects from MLKL-driven lysosomal damage. This article develops an evidence-based framework connecting protease inhibition, amyloid precursor protein cleavage, and necroptosis interpretation without treating one inhibitor as proof of a single mechanism.

• Okadaic Acid A4540: Product Overview

  2026-10-08

  APExBIO lists Okadaic acid A4540 as a marine-derived inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A). The available record supports only a conceptual research scope; no matched paper evidence was provided to independently verify performance, mechanisms, or outcomes.

• MK 0893: Evidence, Mechanism, and Limits

  2026-10-07

  A source-grounded overview of MK 0893 as a glucagon receptor antagonist, covering its allosteric binding site, cellular pharmacology, translational context, and evidence limitations.

• Puromycin Dihydrochloride: Mechanism and Evidence

  2026-10-07

  Puromycin dihydrochloride is an aminonucleoside antibiotic that interrupts translation through a ribosome-dependent mechanism. Its value as a selection marker for pac gene expression and as a translation process study tool is well established conceptually, but reported cellular potency depends on cell type, assay context, and evidence provenance.

• O6-Benzylguanine: Reading MGMT Evidence

  2026-10-06

  O6-Benzylguanine is a mechanism-based MGMT inhibitor that helps separate DNA-repair dependence from broader chemotherapy resistance. This article interprets its value alongside recent findings on AP-2α, MGMT regulation, and temozolomide response, with emphasis on evidence strength and translational limits.

• SUMO Protease (Ulp): Product Overview

  2026-10-06

  APExBIO’s SUMO Protease (Ulp), SKU K1103, is described as a recombinant Ulp1 protease for conceptual SUMO fusion tag cleavage. No matched paper evidence is available, so performance and broader applicability remain supplier-documented.

• Quercetin and NLRP3 in Depression: Study Insights

  2026-10-05

  A 2026 pre-proof study reports that Quercetin reduced depressive-like behaviors and cognitive impairments in an LPS-induced mouse model while suppressing hippocampal NLRP3-associated inflammation. Its main contribution is to connect mood-related behavior, memory performance, and microglial inflammatory signaling, although the findings remain preclinical and do not establish clinical antidepressant efficacy.

• PPACK Dihydrochloride: Evidence and Research Context

  2026-10-05

  PPACK Dihydrochloride is a research reagent used to study thrombin-dependent coagulation and platelet signaling. This overview distinguishes supplier-reported biochemical properties from peer-reviewed evidence, including a study of the separate P2X1 antagonist NF449, and explains the limits of translating those findings to PPACK or clinical anticoagulant use.

• U 46619: TP Receptor Biology and Evidence

  2026-10-04

  U 46619, also called 11,9 epoxymethano-prostaglandin H2, is a synthetic TP-receptor agonist used to study platelet and vascular signaling. Supplier-reported EC50 values distinguish early platelet shape-change responses from later serotonin release, aggregation, and fibrinogen-receptor binding, but the underlying assay conditions are not provided.

• Camostat Mesilate: Evidence, Context, and Limits

  2026-10-03

  Camostat Mesilate is a trypsin-like protease inhibitor studied in epithelial ion transport, fibrotic signaling, and protease-dependent viral entry. The supplied evidence supports these areas unevenly: vendor-reported ENaC and fibrosis findings require primary-source verification, whereas a recent macrocyclic-peptide study provides stronger mechanistic evidence for selective TMPRSS2 inhibition but does not evaluate Camostat Mesilate. This overview compares the evidence, applications, and important limitations without treating pathway-level effects as proof of direct target engagement.

8681 records 1/579 page Next 12345 下5页 Last page